Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug2397 | PTC299 Wiki | 0.71 |
drug2339 | Oral administration of Colchicine plus Herbal Phenolic Monoterpene Fractions Wiki | 0.71 |
drug3182 | Standard Treatment Wiki | 0.71 |
Navigate: Correlations HPO
There are 2 clinical trials
This is a randomized, double-blind, placebo-controlled, multicenter, 28-day study of adult participants hospitalized with COVID-19, with a safety follow-up telephone call at Day 60.
Description: Respiratory improvement is defined as sustained peripheral oxygen saturation (SpO2) ≥94% on room air.
Measure: Time from Randomization to Respiratory Improvement Time: up to Day 28Description: Cough will be rated on a scale of severe, moderate, mild, absent, in those with cough at enrollment rated severe or moderate.
Measure: Time from Randomization to Cough Reported as Mild or Absent Time: up to Day 28Description: Dyspnea will be rated on a scale of severe, moderate, mild, absent, in those with dyspnea at enrollment rated as severe or moderate.
Measure: Time from Randomization to Dyspnea Reported as Mild or Absent Time: up to Day 28This single-center, open-label, 2 arm parallel-group, randomized, interventional prospective exploratory study in 20 subjects aimed to evaluate safety and explore putative clinical benefits of Silmitasertib 1000 mg BID dose in patients with moderate COVID-19. Two-arm trial comparing the SOC/supportive care alone to the SOC/supportive care with addition of Silmitasertib (allocation ratio 1:1).
Description: To assess adverse events associated with the administration of CX-4945 orally, twice daily to patients with moderate COVID-19.
Measure: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]) within the CX-4945 Treatment Group assessed by CTCAE v5.0 Time: From the first day that CX-4945 is taken until the end of the study i.e. 60 days or 46 days after the last dose of CX-4945 is taken.Description: To compare the number of days to clinical recovery specifically associated with COVID-19 in the CX-4945 treatment group as compared to the control arm by Day 14 of the study.
Measure: Clinical Recovery associated with COVID-19 within the CX-4945 Treatment Group Time: First 14 days of the study.Description: To evaluate preliminary evidence of anti-viral activity of CX-4945 as compared to the control arm.
Measure: Anti-Viral Activity of CX-4945 Time: Quantitative changes in viral load from Day 1 to Day 28.Description: To evaluate the maximum plasma concentration of CX-4945 when given at 1000 mg BID PO (Experimental Arm taking CX-4945 only i.e. Group A).
Measure: Maximum Plasma Concentration [Cmax] of CX-4945 Time: Plasma sample of CX-4945 are collected at the following timepoints: Day 1 pre-dose, 0.5, 1, 2, 3, 6 and 24 hours post Day 1 morning dose and Day 14: pre-dose, 0.5, 1, 2, 3, 6, 24, 48 and 72 hours post Day 14 morning dose.Description: Between the experimental arm with CX-4945 and the control arm, moderate COVID-19 patients' health status will be evaluated in terms of all-cause mortality. Mortality status and cause will be assessed by study staff and the information will be documented on a Clinical Status questionnaire. The data collected will be analyzed at the conclusion of the study to determine if there is a statistically significant difference in all-cause mortality between those whose treatment included CX-4945 and those whose treatment did not include CX-4945.
Measure: Clinical Benefit of CX-4945 i.e. All-Cause Mortality Time: Various time points i.e. Day 1, Day 4, Day 8, Day 11, Day 14, Day 15, Day 16, Da y17, Day 28, Day 45 and Day 60.Description: Between the experimental arm with CX-4945 and the control arm, moderate COVID-19 patients' health status will be evaluated in terms of the number of respiratory failures. Respiratory failures will be assessed by study staff and the information will be documented on a Clinical Status questionnaire. The information collected will be analyzed at the conclusion of the study to determine if there is a statistically significant difference in number of respiratory failures between those whose treatment included CX-4945 and those whose treatment did not include CX-4945.
Measure: Clinical Benefit of CX-4945 i.e. Number of Respiratory Failures Time: Various time points i.e. Screening, Day 1, Day 4, Day 8, Day 11, Day 14, Day 28 and Day 45.Description: Between the experimental arm with CX-4945 and the control arm, moderate COVID-19 patients' health status will be evaluated in terms of the number of hospitalized days. The number of hospitalized days will be assessed by study staff and the information will be documented on a Clinical Status questionnaire. The information collected will be analyzed at the conclusion of the study to determine if there is a statistically significant difference in number of hospitalized days between those whose treatment included CX-4945 and those whose treatment did not include CX-4945.
Measure: Clinical Benefit of CX-4945 i.e. Number of Hospitalized Days Time: Various time points i.e. Screening, Day 1, Day 4, Day 8, Day 11, Day 14, Day 28 and Day 45.Description: Between the experimental arm with CX-4945 and the control arm, moderate COVID-19 patients' health status will be evaluated in terms of changes in pulse oxygen saturation. The levels of oxygen saturation will be assessed by study staff measuring the subject's oxygen saturation level, non-invasively and recording the oxygen saturation reading on a Clinical Recovery log. The information collected will be analyzed at the conclusion of the study to determine if there is a statistically significant difference in pulse oxygen saturation between those whose treatment included CX-4945 and those whose treatment did not include CX-4945.
Measure: Clinical Benefit of CX-4945 i.e. Changes in Pulse Oxygen Saturation Time: Various time points i.e. Screening, Day 1, Day 4, Day 8, Day 11, Day 14, Day 28 and Day 45.Description: Between the experimental arm with CX-4945 and the control arm, moderate COVID-19 patients' health status will be evaluated in terms of changes in clinical status. Clinical status (ranging from deceased to not hospitalized/no limitations on activities) will be assessed by study staff and the information will be documented on a Clinical Status questionnaire. The information collected will be analyzed at the conclusion of the study to determine if there is a statistically significant difference in clinical status between those whose treatment included CX-4945 and those whose treatment did not include CX-4945.
Measure: Clinical Benefit of CX-4945 i.e. Changes in Clinical Status Time: Various time points i.e. Screening, Day 1, Day 4, Day 8, Day 11, Day 14, Day 28 and Day 45.Description: Between the experimental arm with CX-4945 and the control arm, moderate COVID-19 patients' health status will be evaluated in terms of subject reported quality of life. Quality of life will be assessed by the subject in relation to Covid-19 related symptoms. The information will be documented on a Clinical Symptom questionnaire. The information collected will be analyzed at the conclusion of the study to determine if there is a statistically significant difference in self-reported quality of life between those whose treatment included CX-4945 and those whose treatment did not include CX-4945.
Measure: Clinical Benefit of CX-4945 i.e. Self-Reported Quality of Life Time: Various time points i.e. Screening, Day 1 - Day 14, Day 28 and Day 45.Description: Labs to evaluate changes in plasma IL-6 (interleukin-6 in pg/mL) levels between the patients within the experimental arm with CX-4945 and the control arm, of patients with moderate COVID-19. The information collected will be analyzed at the conclusion of the study to determine if there is a statistically significant difference in plasma IL-6 levels between those whose treatment included CX-4945 and those whose treatment did not include CX-4945.
Measure: CX-4945 Inflammatory Marker Outcomes i.e. Plasma IL-6 Time: Various time points i.e. Day 1, Day 4, Day 8, Day 11 and Day 14.Description: Labs to evaluate changes in plasma CRP (C-reactive protein in mg/DL) levels between the patients within the experimental arm with CX-4945 and the control arm, of patients with moderate COVID-19. The information collected will be analyzed at the conclusion of the study to determine if there is a statistically significant difference in plasma CRP levels between those whose treatment included CX-4945 and those whose treatment did not include CX-4945.
Measure: CX-4945 Inflammatory Marker Outcomes i.e. Plasma CRP Time: Various time points i.e. Screening, Day 1, Day 4, Day 8, Day 11, Day 14, Day 28 and Day 45.Description: Labs to evaluate changes in plasma LDH (lactic acid dehydrogenase in U/L) levels between the patients within the experimental arm with CX-4945 and the control arm, of patients with moderate COVID-19. The information collected will be analyzed at the conclusion of the study to determine if there is a statistically significant difference in plasma LDH levels between those whose treatment included CX-4945 and those whose treatment did not include CX-4945.
Measure: CX-4945 Inflammatory Marker Outcomes i.e. Plasma LDH Time: Various time points i.e. Screening, Day 1, Day 4, Day 8, Day 11, Day 14, Day 28 and Day 45.Description: Labs to evaluate changes in plasma CPK (creatine phosphokinase in mcg/L) levels between the patients within the experimental arm with CX-4945 and the control arm, of patients with moderate COVID-19. The information collected will be analyzed at the conclusion of the study to determine if there is a statistically significant difference in plasma CPK levels between those whose treatment included CX-4945 and those whose treatment did not include CX-4945.
Measure: CX-4945 Inflammatory Marker Outcomes i.e. Plasma CPK Time: Various time points i.e. Screening, Day 1, Day 4, Day 8, Day 11, Day 14, Day 28 and Day 45.Description: Labs to evaluate changes in plasma ferritin (mcg/L) levels between the patients within the experimental arm with CX-4945 and the control arm, of patients with moderate COVID-19. The information collected will be analyzed at the conclusion of the study to determine if there is a statistically significant difference in plasma ferritin levels between those whose treatment included CX-4945 and those whose treatment did not include CX-4945.
Measure: CX-4945 Inflammatory Marker Outcomes i.e. Plasma Ferritin Time: Various time points i.e. Screening, Day 1, Day 4, Day 8, Day 11, Day 14, Day 28 and Day 45.Description: Labs to evaluate changes in plasma D-dimer (ng/mL) levels between the patients within the experimental arm with CX-4945 and the control arm, of patients with moderate COVID-19. The information collected will be analyzed at the conclusion of the study to determine if there is a statistically significant difference in plasma D-dimer levels between those whose treatment included CX-4945 and those whose treatment did not include CX-4945.
Measure: CX-4945 Inflammatory Marker Outcomes i.e. Plasma D-Dimer Time: Various time points i.e. Screening, Day 1, Day 4, Day 8, Day 11, Day 14, Day 28 and Day 45.Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports